Published in Isr J Med Sci on February 08, 1989
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83
Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med (1999) 4.22
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res (1994) 3.30
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer (2002) 2.34
Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet (1997) 2.31
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet (1997) 2.28
High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history. Gynecol Oncol (1997) 2.25
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A (2001) 2.09
Thermoradiotherapy for residual microscopic cancer: elective or post-excisional hyperthermia and radiation therapy in the management of local-regional recurrent breast cancer. Int J Radiat Oncol Biol Phys (1992) 2.08
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol (2000) 1.98
Prevalence of sleep apnea syndrome among patients with essential hypertension. Am Heart J (1984) 1.83
Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole. Cancer Res (1980) 1.78
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol (1989) 1.69
Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol (2001) 1.69
Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol (1996) 1.59
Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol (2000) 1.52
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer (2000) 1.51
Giant melanoma of the inner thigh: a homeopathic life-threatening negligence. Ann Plast Surg (1991) 1.48
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer (2004) 1.41
Defining alternative medicine. Isr Med Assoc J (2002) 1.38
Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis (1995) 1.34
Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet (1984) 1.31
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer (2001) 1.27
Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol (1994) 1.22
Low PSA metastatic androgen- independent prostate cancer. Eur Urol (2000) 1.20
The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet (1999) 1.19
Two-stage plans for patient accrual in phase II cancer clinical trials. Cancer Treat Rep (1980) 1.19
Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril (1996) 1.16
Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res (1979) 1.14
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer (2003) 1.12
Cancer patient expectations of and communication with oncologists and oncology nurses: the experience of an integrated oncology and palliative care service. Support Care Cancer (2000) 1.12
ESMO takes a stand on supportive and palliative care. Ann Oncol (2003) 1.12
Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer (2006) 1.12
PAGET'S DISEASE AND MALE BREAST CANCER. Isr Med Assoc J (2015) 1.08
Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood (1996) 1.08
Tumor suppressor p53 regulates heparanase gene expression. Oncogene (2006) 1.07
Small cell lung cancer: analysis of treatment factors contributing to prolonged survival. Cancer (1981) 1.05
Preimplantation genetic diagnosis for BRCA1/2--a novel clinical experience. Prenat Diagn (2009) 1.05
Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis. J Mammary Gland Biol Neoplasia (2001) 1.04
Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br J Cancer (1991) 1.02
Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer (2013) 1.02
The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. Br J Cancer (2001) 1.01
European Society for Medical Oncology (ESMO) Program for the integration of oncology and Palliative Care: a 5-year review of the Designated Centers' incentive program. Ann Oncol (2009) 1.01
Primary colorectal sarcoma. A retrospective review and prognostic factor study of 50 consecutive patients. Arch Surg (1990) 1.00
Clinical diagnosis of secondary tumors of the heart and pericardium. Dis Chest (1969) 1.00
Follow-up neurological evaluation in patients with small cell lung carcinoma treated with prophylactic cranial irradiation and chemotherapy. Int J Radiat Oncol Biol Phys (1981) 0.99
Prognostic factors for local control of early glottic cancer: the Rabin Medical Center retrospective study on 207 patients. Int J Radiat Oncol Biol Phys (1999) 0.99
Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol (1989) 0.98
The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. Int J Cancer (1996) 0.98
Second neoplasms in patients with Merkel cell carcinoma. Cancer (2001) 0.98
Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed Pharmacother (2005) 0.97
Magnetic resonance guided focused ultrasound surgery. Ablation of soft tissue at bone-muscle interface in a porcine model. Eur J Clin Invest (2008) 0.97
Brain metastasis from prostatic carcinoma. Cancer (1976) 0.97
Chemotherapy of advanced, hormonally resistant prostatic carcinoma. Oncology (1980) 0.96
The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. Cancer (1997) 0.96
A hazard of cuffed flexo-metallic endotracheal tubes. Br J Anaesth (1969) 0.96
Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol) (2007) 0.96
Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer (2007) 0.95
A deletion/insertion mutation in the BRCA2 gene in a breast cancer family: a possible role of the Alu-polyA tail in the evolution of the deletion. Genes Chromosomes Cancer (2001) 0.95
The rediscovery of DON (6-diazo-5-oxo-L-norleucine). Recent Results Cancer Res (1980) 0.94
Cancer pain: knowledge and attitudes of physicians in Israel. J Pain Symptom Manage (1999) 0.92
5-Fluorouracil, doxorubicin (adriamycin) and mitomycin-C (FAM) in advanced gastric cancer: observations on response, patient characteristics, myelosuppression and delivered dosage. Oncology (1989) 0.92
Radiocurability of microscopic disease in childhood rhabdomyosarcoma with radiation doses less than 4,000 cGy. J Clin Oncol (1990) 0.92
Overview of Taxol safety. J Natl Cancer Inst Monogr (1993) 0.91
Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis. A morphologic and adriamycin-penetration study. J Neurooncol (1987) 0.91
Therapeutic irradiation of the chest and electrocardiographic changes. Clin Radiol (1969) 0.91
Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered (2001) 0.91
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma. Br J Cancer (2004) 0.91
Decline in pulmonary function in patients with breast cancer receiving dose-dense chemotherapy: a prospective study. Ann Oncol (2009) 0.91
Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin. Oncogene (2009) 0.90
Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet (1998) 0.90
Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol (1994) 0.90
EZH2 promotes a bi-lineage identity in basal-like breast cancer cells. Oncogene (2013) 0.90
Early development of vaginal shortening during radiation therapy for endometrial or cervical cancer. Int J Gynecol Cancer (2001) 0.90
Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer (2002) 0.90
A new human ovarian carcinoma cell line: establishment and analysis of tumor-associated markers. Oncology (1985) 0.90
Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. Gynecol Oncol (2003) 0.90
Phase I and clinical pharmacological evaluation of aphidicolin glycinate. J Natl Cancer Inst (1991) 0.90
Phosphorylation of a K+ channel alpha subunit modulates the inactivation conferred by a beta subunit. Involvement of cytoskeleton. J Biol Chem (1996) 0.89
Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst (1979) 0.89
[Solitary metastatic involvement of the spleen in squamous cell carcinoma of the cervix]. Harefuah (1977) 0.89
Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group. Ann Oncol (1994) 0.88
Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity. Cancer Treat Rep (1979) 0.88
The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction. Am J Hum Genet (1998) 0.88
Effect of natural beta-carotene supplementation in children exposed to radiation from the Chernobyl accident. Radiat Environ Biophys (1998) 0.88
The management of pericardial effusion in cancer patients. Chest (1977) 0.88
Correlation of erythrocyte and plasma levels of zinc, copper, and iron with evidence of metastatic spread in cancer patients. Cancer (1985) 0.87
Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br J Cancer (2008) 0.87
Topical Biafine and Lipiderm for the prevention of radiation dermatitis: a randomized prospective trial. Oncol Rep (2001) 0.87
Palliative medicine and the medical oncologist. Defining the purview of care. Hematol Oncol Clin North Am (1996) 0.87